Dataset 3: Raw data for Figure 3, Incremental cost-effectiveness plane for once daily (QD) versus twice-daily regimen (BID).
Rattachement africain : se, Afrique du Sud, gb, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: Regimen simplification of ART, by administering them less frequently, has been suggested as a practical approach to improve adherence. The aim of this study was to assess the cost-utility of once-daily (QD) versus twice-daily (BID) antiretroviral (ART) regimens in the treatment of HIV. METHODS: A Model-based Markov modelling of cost-effectiveness using secondary data sources was developed to determine the incremental cost per quality-adjusted life year (QALY) gained of QD versus BID ART regimen for a hypothetical cohort treatment-naïve adults with HIV, from the Sub-Saharan African healthcare payer’s perspective. RESULTS: At base-case values for all parameters, the total number of QALY gained by QD regimen was 0.27 and the incremental cost difference of $2147.04. The incremental cost-effectiveness ratio (ICER) of QD versus BID regimen was $8087/QALY gained. The ICER was most sensitive to the variations in the total medical cost of state A (asymptomatic, non-AIDS, CD4> 350 cells/μL), total medical Cost State D (symptomatic AIDS or severe symptoms), and utility of State A. In our bootstrap analysis, 60% of bootstrap replicates for the ICER shows that QD is more costly and more effective than BID regimen, while the remaining 40% replicates shows that QD is less costly and less effective than BID. If decision-makers were willing to pay $1000 per QALY gained, the probability of QD being cost-effective was 44%. The probability of QD regimen being cost-effective was 48% when the willing to pay was $5000. CONCLUSIONS: From a sub-Saharan Africa societal perspective QD regimen cannot be regarded as cost-effective, although there is substantial decision uncertainty. Findings from the economic evaluation are important for low- and middle-income countries (LMIC) to consider as they decide whether to adopt the new branded single tablet regimen. Generic-based ART could yield substantial budgetary saving to HIV programmes in LMIC.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé, mais le titre doit être comparé manuellement.
- Titre Crossref
- <b>Dataset 3: </b>Raw data for Figure 3, Incremental cost-effectiveness plane for once daily (QD) versus twice-daily regimen (BID).
- Date Crossref
- 24/11/2025
- Éditeur
- F1000 Research Ltd
- Type
- dataset
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Karolinska University Hospital Department of Public Health (IHCAR) pays non établi dans la noticeÉtablissement de santé
-
Stellenbosch University Centre for Evidence-based Health Care Stellenbosch University, Afrique du Sud (code pays fourni par la source)Université ou école supérieure
-
Karolinska Institutet pays non établi dans la noticeUniversité ou école supérieure
-
University of Warwick Warwick Medical School pays non établi dans la noticeUniversité ou école supérieure
-
Johns Hopkins University pays non établi dans la noticeUniversité ou école supérieure
-
University of Pittsburgh pays non établi dans la noticeUniversité ou école supérieure
-
Tygerberg Hospital Afrique du Sud (code pays fourni par la source)Établissement de santé
-
Center for Evidence-Based Global Health Minna, Nigéria (ville ou établissement reconnu, pays non nommé)Institution
-
Johns Hopkins Bloomberg School of Public Health Department of Epidemiology and International Health pays non établi dans la noticeUniversité ou école supérieure
-
Pittsburgh Graduate School of Public Health pays non établi dans la noticeUniversité ou école supérieure
Department of Public Health (IHCAR) — Karolinska University Hospital, Centre for Evidence-based Health Care — Stellenbosch University (Stellenbosch University, Afrique du Sud) et Karolinska Institutet, avec 7 autres affiliations. Pays d’affiliation : Afrique du Sud, Nigéria.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.